Rocket Pharmaceuticals Inc (NAS:RCKT)
$ 23 0.77 (3.46%) Market Cap: 2.09 Bil Enterprise Value: 1.71 Bil PE Ratio: 0 PB Ratio: 4.72 GF Score: 43/100

Rocket Pharmaceuticals Inc at UBS Global Healthcare Conference Transcript

May 24, 2022 / 11:45AM GMT
Release Date Price: $9.99 (-7.84%)
Colin Nigel Bristow
UBS Investment Bank, Research Division - Analyst

Well, good morning, everyone, and welcome to day 2 of the UBS Global Healthcare Conference. It is my pleasure to host Rocket Pharmaceuticals here today. From the company, we have Gaurav Shah, the CEO. If anyone has a question, there's a QR code, you can scan it. And all being well, the question should pop up on the iPad here, and I can field it for you.

I think -- Gaurav, I'm sure you have a few sort of opening remarks, especially with the positive data recently. So I'll turn it over to you, and then we can dig into some questions.

Gaurav D. Shah
Rocket Pharmaceuticals, Inc. - CEO & Director

Thanks, Colin, for having us here, at the UBS. Good to see everybody. Not very often we come back to live conferences, so this feels really good. So Rocket Pharma, we're a gene therapy company. We're a multi-platform or platform agnostic, depending on how you think about it. And we have 2 platforms. One is an in vivo AAV platform. Right now, we apply to a cardiology disease called Danon

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot